Current Progress and Future With Glembatumumab Vedotin in TNBC

November 11, 2016
Linda T. Vehdat, MD, PhD

Linda T. Vahdat, MD, PhD, ‎Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the current progress being made with glembatumumab vedotin in triple-negative breast cancer (TNBC) and what the future holds for this agent.